Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma NetworkOlivier Hermine, Martin Dreyling, Michael Hallek et al.|The Lancet|2016Cited by 401
Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly TrialHanneke C. Kluin‐Nelemans, Martin Dreyling, Eva Hoster et al.|Journal of Clinical Oncology|2019Cited by 143
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma NetworkMartin Dreyling, Eva Hoster, Jeanette K. Doorduijn et al.|The Lancet|2024Cited by 135
High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma NetworkOlivier Hermine, Linmiao Jiang, Jan Walewski et al.|Journal of Clinical Oncology|2022Cited by 56
Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trialAnna‐Katharina Zoellner, Eva Hoster, Michael Unterhalt et al.|The Lancet Haematology|2021Cited by 53